Variability of Serum Concentration of Calcium, Phosphate and Parathyroid Hormone Depending on Time of Blood Draw for Patients on Nocturnal Home Hemodialysis


Background: Guidelines for patients treated with conventional hemodialysis patients have been written for target serum levels for calcium (Ca), phosphate (PO4) and intact parathyroid hormone (iPTH). No guidelines exist for nocturnal home hemodialysis (NHHD) patients for target values or timing of the blood sample draw. We undertook a prospective cohort study to examine the variability in pre, post and clinic (post-post) serum values for Ca, PO4, and iPTH in NHHD patients to determine if timing of blood draw could affect clinical decisions. Methods: Twenty prevalent NHHD patients collected blood pre and post their usual NHHD session with an additional blood sample drawn in clinic (post-post). Median and interquartile range of pre, post and clinic (post-post) values of iPTH, PO4 and Ca were calculated and compared with Freidman/Wilcoxon test. Serum concentrations were also categorized according to Canadian Society of Nephrology (CSN) guidelines target values for pre and clinic (post-post) samples. The proportion of patients that would be categorized differently by clinic (post-post) samples was determined. Results: There was a significant difference between pre-serum values compared to post and clinic (post-post) values. Overall, iPTH, PO4 and Ca values would be misclassified in 25%, 70% and 50% respectively if blood was drawn at the clinic visit (post-post) compared to pre-HD as per CSN guidelines. Conclusions: Although no specific guideline has been written for NHHD patients, to ensure consistency of management compared to in-centre HD patients, lab values should be drawn pre-HD until clinical evidence suggests that the recommendations should be different for NHHD.

Share and Cite:

N. Shahbazi, P. Brown, A. Akbari and D. Zimmerman, "Variability of Serum Concentration of Calcium, Phosphate and Parathyroid Hormone Depending on Time of Blood Draw for Patients on Nocturnal Home Hemodialysis," Open Journal of Nephrology, Vol. 2 No. 4, 2012, pp. 65-71. doi: 10.4236/ojneph.2012.24011.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] A. Laupacis, P. Keown, N. Pus, et al., “A Study of the Quality of Life and Cost-Utility of Renal Transplant,” Kidney International, Vol. 50, No. 1, 1996, pp. 235-242. doi:10.1038/ki.1996.307
[2] B. F. Culleton, M. Walsh, S. W. Klarenbach, et al., “Effect of Frequent Nocturnal Hemodialysis vs Conventional Hemodialysis on Left Ventricular Mass and Quality of Life: A Randomized Controlled Trial,” Journal of the American Medical Association, Vol. 298, No. 11, 2007, pp. 1291-1299. doi:10.1001/jama.298.11.1291
[3] P. A. McFarlane, A. M. Bayoumi, A. Pierratos and D. A. Redelmeier, “The Quality of Life and Cost Utility of Home Nocturnal and Conventional in-Center Hemodialysis,” Kidney International, Vol. 64, No. 3, 2003, pp. 1004-1011. doi:10.1046/j.1523-1755.2003.00157.x
[4] M. V. Rocco, R. S. Lockridge, Jr, G. J. Beck, et al., “The Effects of Frequent Nocturnal Home Hemodialysis: The Frequent Hemodialysis Network Nocturnal Trial,” Kidney International, Vol. 80, No. 10, 2011, pp. 1080-1091. doi:10.1038/ki.2011.213
[5] M. John and K. Michael, “Starting a Home Hemodialysis Program,” Seminars in Dialysis, Vol. 20, No. 1, 2007, pp. 35-39. doi:10.1111/j.1525-139X.2007.00239.x
[6] R. Mactier, N. Hoenich, C. Breen, “Renal Assocition Clinical Practice Guidelines 5th Edition 2009-2012,” Nephron Clinical Practice, Vol. 118, Suppl. 1, 2011, pp. 241-286.
[7] S. Moe, T. Drueke, J. Cunningham, et al., “Definition, Evaluation, and Classification of Renal Osteodystrophy: A Position Statement from Kidney Disease: Improving Global Outcomes (KDIGO),” Kidney International, Vol. 69, No. 11, 2006, pp. 1945-1953. doi:10.1038/
[8] W. G. Goodman, J. Goldin, B. D. Kuizon, et al., “Coronary Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing Dialysis,” The New England Journal of Medicine, Vol. 342, No. 20, 2000, pp. 1478-1483. doi:10.1056/NEJM200005183422003
[9] W. Y. Qunibi, C. A. Nolan and J. C. Ayus, “Cardiovascular Calcification in Patients with End-Stage Renal Disease: A Century Old Phenomenon,” Kidney International, Vol. 62, Suppl. 82, 2002, pp. S73-S80. doi:10.1046/j.1523-1755.62.s82.15.x
[10] G. A. Block, P. S. Klassen, J. M. Lazarus, N. Ofsthun, E. G. Lowrie and G. M. Chertow, “Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis,” Journal of the American Society of Nephrology, Vol. 15, No. 8, 2004, pp. 2208-2218. doi:10.1097/01.ASN.0000133041.27682.A2,
[11] M. L. Melamed, J. A. Eustace, L. Plantinga, et al., “Changes in Serum Calcium, Phosphate, and PTH and the Risk of Death in Incident Dialysis Patients: Along Longitudinal Study,” Kidney International, Vol. 70, 2006, pp. 351-357. doi:10.1038/
[12] National Kidney Foundation, “K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease,” American Journal of Kidney Diseases, Vol. 42, Suppl. 3, 2003, pp. S1-S201. doi:10.1016/S0272-6386(03)00553-5
[13] K. Jindal, C. T. Chan, C. Deziel, et al., “Hemodialysis Clinical Practice Guidelines for the Canadian Society of Nephrology,” Journal of the American Society of Nephrology, Vol. 17, No. 3, 2006, pp. S1-S27.
[14] Joint Specialty Committee on Renal Medicine of the Royal College of Physicians and the Renal Association, and the Royal College of General Practitioners, “Chronic Kidney Disease in Adults: UK Guidelines for Identification, Management and Referral,” Royal College of Physicians, London, 2006.
[15] G. Elder, R. Faull, P. Branley and C. Hawley, “Management of Bone Disease, Calcium, Phosphate and Parathyroid Hormone,” Nephrology, Vol. 11, Suppl. 1, 2006, pp. S230-S261. doi:10.1111/j.1440-1797.2006.00508.x
[16] CKD-MBD Work Group, “KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),” Kidney International, Vol. 113, 2009, pp. S1-130.
[17] J. B Cannata-Andía, T. B. Drueke, J. Cunningham, et al., “Clinical Algorithms on Renal Osteodystrophy,” Nephrology Dialysis Transplantation, Vol. 15, Suppl. 5, 2000, pp. S39-S57.
[18] F. Tentori, M. J. Blayney, J. M. Albert, et al., “Mortality Risk for Dialysis Patients with Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS),” American Journal of Kidney Diseases, Vol. 52, No. 3, 2008, pp. 519-553. doi:10.1053/j.ajkd.2008.03.020
[19] G. A. Block, P. S. Klassen, J. M. Lazarus, N. Ofsthun, E. G. Lowrie and G. M. Chertow, “Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis,” Journal of the American Society of Nephrology, Vol. 15, No. 8, 2004, 2208-2218. doi:10.1097/01.ASN.0000133041.27682.A2
[20] R. M. Lindsay, F. Alhejaili, G. Nesrallah, et al., “Calcium and Phosphate Balance with Quotidian Hemodialysis,” American Journal of Kidney Diseases, Vol. 42, No. 1, 2003, pp. S24-S29. doi:10.1016/S0272-6386(03)00534-1
[21] N. Toussaint, J. Boddington, R. Simmonds, C. Waldron, C. Soerville and J. Agar, “Calcium Phosphate Metabolism and Bone Mineral Density with Nocturnal Hemodialysis,” HHemodialysis International, Vol. 10, No. 3, 2006, pp. 280-286. doi:10.1111/j.1542-4758.2006.00109.x

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.